Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapport Therapeutics (RAPP) Accumulated Depreciation (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Accumulated Depreciation data on record, last reported at $1.9 million in Q1 2026.

  • On a quarterly basis, Accumulated Depreciation rose 59.5% to $1.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.9 million, a 59.5% increase, with the full-year FY2025 number at $2.0 million, up 105.39% from a year prior.
  • Accumulated Depreciation reached $1.9 million in Q1 2026 per RAPP's latest filing, down from $2.0 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation for RAPP hit a ceiling of $2.0 million in Q4 2025 and a floor of $127000.0 in Q4 2023.
  • A 4-year average of $1.2 million and a median of $1.2 million in 2025 define the central range for Accumulated Depreciation.
  • Peak YoY movement for Accumulated Depreciation: soared 659.84% in 2024, then soared 59.5% in 2026.
  • Tracing RAPP's Accumulated Depreciation over 4 years: stood at $127000.0 in 2023, then skyrocketed by 659.84% to $965000.0 in 2024, then surged by 105.39% to $2.0 million in 2025, then fell by 2.62% to $1.9 million in 2026.
  • Business Quant data shows Accumulated Depreciation for RAPP at $1.9 million in Q1 2026, $2.0 million in Q4 2025, and $1.7 million in Q3 2025.